Profile data is unavailable for this security.
About the company
Smith & Nephew plc is a portfolio medical technology company. The Company is engaged in developing, manufacturing, marketing, and selling medical devices and services. It is focused on the repair, regeneration, and replacement of soft and hard tissue. Its segments include Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Its Orthopaedics segment includes a range of hip and knee Implants used to replace diseased, damaged or worn joints, robotics-assisted and digital enabling technologies and services that help surgeons, and trauma products used to stabilize severe fractures and correct hard tissue deformities. Its Sports Medicine & Ear, Nose and Throat (ENT) businesses offer advanced products and instruments used to repair or remove soft tissue. Its Advanced Wound Management portfolio provides a comprehensive set of products to meet broad and complex clinical needs, and to help healthcare professionals reduce the human and economic consequences of wounds.
- Revenue in USD (TTM)5.64bn
- Net income in USD305.00m
- Incorporated1937
- Employees18.00k
- LocationSmith & Nephew PLCBuilding 5, Croxley Park, Hatters LaneWATFORD WD18 8YEUnited KingdomGBR
- Phone+44 207 401 7646
- Fax+44 207 930 3353
- Websitehttps://www.smith-nephew.com/
More ▼
Mergers & acquisitions
| Acquired company | SN.:LSE since announced | Transaction value |
|---|---|---|
| Cartiheal 2009 Ltd | 13.75% | 330.00m |
Data delayed at least 20 minutes, as of Sep 19 2024 16:07 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lantheus Holdings Inc | 1.44bn | 428.48m | 7.51bn | 834.00 | 17.71 | 7.31 | 15.37 | 5.22 | 6.11 | 6.11 | 20.48 | 14.79 | 0.8775 | 8.35 | 4.58 | 1,724,234.00 | 26.15 | 6.69 | 29.96 | 7.73 | 64.49 | 57.56 | 29.80 | 9.02 | 4.41 | -- | 0.3546 | 0.00 | 38.65 | 30.44 | 1,063.86 | 51.81 | 35.48 | -- |
| Penumbra Inc | 1.13bn | 14.23m | 7.60bn | 4.20k | 572.71 | 6.54 | 175.16 | 6.70 | 0.3415 | 0.3415 | 28.94 | 29.90 | 0.7642 | 1.07 | 5.53 | 269,924.50 | 0.9595 | 2.32 | 1.07 | 2.61 | 65.45 | 63.90 | 1.26 | 3.17 | 3.77 | -- | 0.0209 | 0.00 | 24.95 | 18.93 | 4,643.16 | 68.60 | 9.64 | -- |
| Repligen Corp | 602.35m | -1.90m | 7.95bn | 1.78k | -- | 4.00 | 115.96 | 13.21 | -0.0416 | -0.0416 | 10.67 | 35.53 | 0.2226 | 1.46 | 4.95 | 337,831.80 | -0.0703 | 4.38 | -0.0782 | 5.03 | 47.70 | 55.43 | -0.3156 | 15.91 | 5.56 | -- | 0.2282 | 0.00 | -20.31 | 26.91 | -77.64 | 20.13 | 24.99 | -- |
| Henry Schein, Inc. | 12.49bn | 352.00m | 9.18bn | 25.00k | 26.79 | 2.62 | 14.55 | 0.7353 | 2.71 | 2.71 | 95.98 | 27.64 | 1.29 | 4.88 | 8.25 | 499,480.00 | 3.58 | 6.09 | 5.97 | 10.44 | 31.63 | 30.04 | 2.78 | 4.40 | 0.896 | 6.85 | 0.3333 | 0.00 | -2.44 | 5.55 | -22.68 | -0.1456 | 21.27 | -- |
| Bio Rad Laboratories Inc | 2.56bn | -1.33bn | 9.42bn | 8.03k | -- | 1.42 | -- | 3.68 | -47.03 | -47.03 | 89.18 | 240.39 | 0.2366 | 1.49 | 5.47 | 319,128.80 | -12.24 | 9.08 | -12.87 | 9.60 | 54.02 | 55.55 | -51.73 | 41.97 | 4.63 | 0.1653 | 0.1504 | 0.00 | -4.67 | 3.13 | 82.43 | -- | 3.83 | -- |
| Globus Medical Inc | 2.24bn | 40.68m | 9.42bn | 5.00k | 234.44 | 2.37 | 34.99 | 4.21 | 0.2968 | 0.2968 | 17.02 | 29.38 | 0.6207 | 1.63 | 5.25 | 447,306.00 | 1.13 | 6.90 | 1.30 | 7.45 | 59.65 | 71.73 | 1.82 | 14.05 | 1.45 | 455.56 | 0.098 | 0.00 | 53.34 | 17.08 | -35.39 | -4.72 | 5.57 | -- |
| Bruker Corp | 3.12bn | 352.10m | 10.11bn | 9.71k | 27.80 | 5.65 | 20.41 | 3.24 | 2.40 | 2.40 | 21.24 | 11.82 | 0.6393 | 1.47 | 5.90 | 321,386.60 | 7.21 | 8.38 | 9.59 | 11.40 | 50.08 | 49.85 | 11.28 | 11.39 | 0.7244 | 43.06 | 0.5419 | 9.81 | 17.14 | 9.36 | 44.03 | 18.91 | 16.79 | 4.56 |
| Teleflex Inc | 3.01bn | 264.76m | 11.38bn | 14.50k | 43.17 | 2.50 | 21.85 | 3.78 | 5.59 | 5.57 | 63.54 | 96.76 | 0.4196 | 2.09 | 6.85 | 207,437.10 | 3.69 | 5.86 | 4.00 | 6.42 | 55.86 | 54.43 | 8.80 | 14.62 | 1.44 | 7.14 | 0.2737 | 15.84 | 6.57 | 3.97 | -1.47 | 12.73 | 2.51 | 0.00 |
| Smith & Nephew plc (ADR) | 5.64bn | 305.00m | 13.43bn | 18.00k | 43.97 | 2.58 | 13.93 | 2.38 | 0.6985 | 0.6985 | 12.92 | 11.91 | 0.5535 | 0.7128 | 4.30 | 305,766.30 | 2.99 | 4.10 | 3.62 | 4.99 | 69.04 | 71.39 | 5.41 | 8.02 | 1.11 | 5.48 | 0.4125 | 79.59 | 6.40 | 2.50 | 17.94 | -16.88 | 4.24 | -- |
| Revvity Inc | 2.71bn | 197.34m | 15.37bn | 11.50k | 78.01 | 1.95 | 24.53 | 5.67 | 1.60 | 1.37 | 21.90 | 63.80 | 0.1959 | 2.89 | 4.42 | 235,499.60 | 1.43 | 4.76 | 1.59 | 5.39 | 55.26 | 57.19 | 7.29 | 15.34 | 1.98 | 6.89 | 0.3299 | 6.52 | -16.95 | -0.1982 | -64.99 | -5.28 | -2.69 | 0.00 |
| Insulet Corp | 1.87bn | 395.30m | 16.55bn | 3.00k | 43.62 | 16.58 | 35.16 | 8.84 | 5.41 | 5.41 | 24.53 | 14.24 | 0.711 | 1.38 | 6.25 | 624,233.30 | 15.01 | 2.71 | 18.15 | 3.14 | 69.00 | 65.81 | 21.11 | 4.28 | 2.71 | 87.97 | 0.5833 | 0.00 | 30.02 | 24.66 | 4,384.78 | 128.77 | -7.63 | -- |
| Avantor Inc | 6.83bn | 360.20m | 18.40bn | 14.50k | 51.10 | 3.38 | 24.17 | 2.70 | 0.5295 | 0.5295 | 10.03 | 8.00 | 0.530 | 5.37 | 5.82 | 470,731.00 | 2.80 | 2.97 | 3.17 | 3.35 | 33.71 | 33.44 | 5.28 | 5.06 | 1.05 | 3.07 | 0.4848 | 0.00 | -7.26 | 3.51 | -51.52 | -- | 31.17 | -- |
| Align Technology, Inc. | 3.94bn | 447.03m | 18.90bn | 21.61k | 42.91 | 5.03 | 32.20 | 4.79 | 5.90 | 5.90 | 52.03 | 50.31 | 0.641 | 4.16 | 4.09 | 182,455.40 | 7.27 | 16.34 | 10.96 | 24.14 | 69.82 | 71.72 | 11.34 | 23.16 | 1.06 | -- | 0.00 | 0.00 | 3.42 | 14.45 | 23.09 | 2.15 | -4.46 | -- |
| Hologic Inc | 3.99bn | 701.50m | 18.98bn | 6.99k | 27.89 | 3.83 | 18.77 | 4.76 | 2.93 | 2.93 | 16.59 | 21.33 | 0.4375 | 2.64 | 6.06 | 570,472.10 | 7.70 | 11.40 | 8.64 | 13.38 | 55.41 | 60.29 | 17.59 | 20.95 | 3.32 | 709.77 | 0.3408 | 0.00 | -17.12 | 4.61 | -64.98 | -- | 7.30 | -- |
| Waters Corp | 2.88bn | 595.69m | 19.79bn | 7.90k | 33.21 | 14.01 | 25.13 | 6.88 | 10.04 | 10.04 | 48.46 | 23.79 | 0.6394 | 2.19 | 4.41 | 364,118.20 | 13.24 | 19.77 | 16.04 | 25.29 | 59.68 | 58.45 | 20.71 | 23.38 | 1.42 | 8.74 | 0.5869 | 0.00 | -0.5229 | 4.09 | -9.26 | 1.53 | 4.72 | -- |
Data as of Sep 19 2024. Currency figures normalised to Smith & Nephew PLC's reporting currency: US Dollar USD
4.34%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fiduciary Management, Inc.as of 30 Jun 2024 | 4.36m | 1.00% |
| Barrow, Hanley, Mewhinney & Strauss LLCas of 30 Jun 2024 | 4.18m | 0.96% |
| Scharf Investments LLCas of 30 Jun 2024 | 2.99m | 0.68% |
| Brandes Investment Partners LPas of 30 Jun 2024 | 1.37m | 0.31% |
| J. Goldman & Co. LPas of 30 Jun 2024 | 1.33m | 0.31% |
| BMO Asset Management Corp.as of 30 Jun 2024 | 1.23m | 0.28% |
| Parametric Portfolio Associates LLCas of 30 Jun 2024 | 996.11k | 0.23% |
| Goldman Sachs Asset Management LPas of 30 Jun 2024 | 970.76k | 0.22% |
| Bank of America, NA (Private Banking)as of 30 Jun 2024 | 764.97k | 0.18% |
| The Clark Estates, Inc.as of 30 Jun 2024 | 750.00k | 0.17% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
